Current Pharmaceutical Design
Title:Editorial: Towards MiRNA Based Therapeutics for Lung Cancer
Volume: 23 Issue: 39
Author(s): Qun Zhou, Cheng-Cao Sun*De-Jia Li*
Affiliation:
- Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan 430071, Hubei,China
- Department of Occupational and Environmental Health, School of Public Health, Wuhan University, Wuhan 430071, Hubei,China
Export Options
About this article
Cite this article as:
Zhou Qun , Sun Cheng-Cao *, Li De-Jia *, Editorial: Towards MiRNA Based Therapeutics for Lung Cancer, Current Pharmaceutical Design 2017; 23 (39) . https://dx.doi.org/10.2174/138161282339180212095249
DOI https://dx.doi.org/10.2174/138161282339180212095249 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
38
3
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
Current Drug Targets Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs Foamy Virus Vectors: An Awaited Alternative to Gammaretro- and Lentiviral Vectors
Current Gene Therapy The Impact of the Emerging Genomics Data on the Management of Agerelated Phenotypes in the Context of Cellular Senescence
Current Drug Targets The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry Naphthoflavones as Antiproliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Novel Oncogenic Protein Kinase Inhibitors for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents A Dual Role for Sirtuin 1 in Tumorigenesis
Current Pharmaceutical Design DNA Mismatch Repair Deficiency, Resistance to Cancer Chemotherapy and the Development of Hypersensitive Agents
Current Topics in Medicinal Chemistry Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Molecular Targets of Ovarian Carcinomas with Acquired Resistance to Platinum/Taxane Chemotherapy
Current Cancer Drug Targets Small Molecule Inhibitors of p53/MDM2 Interaction
Current Topics in Medicinal Chemistry The Place of the Bioisosteric Sila-Substitution in Drug Design
Drug Design Reviews - Online (Discontinued) Immune Checkpoint Inhibitors in AML-A New Frontier
Current Cancer Drug Targets Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias
Current Cancer Drug Targets Transcriptional Regulation of Antimicrobial Host Defense Peptides
Current Protein & Peptide Science Synthesis and Antitumor Evaluation of Thiophene Analogs of Kigelinone
Letters in Organic Chemistry